MAZE

$27.67+$0.13 (+0.49%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$1.5B

56M shares

52-week range

$12.81 – $53.65

36% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change+$11.71

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$22M	+604.0%	$-2.73	$-3.10–$-2.00	—	7
2027	$16M	-26.3%	$-3.22	$-4.50–$-2.27	—	7
2028	$12M	-23.2%	$-3.64	$-5.93–$-2.74	—	6
2029	$51M	+309.4%	$-3.86	$-3.86–$-3.86	—	3

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-12	$-0.72	$-0.76	-6.0%
2026-05-12	$-0.43	$-0.45	-4.7%
2026-03-25	$-0.73	$-0.65	+11.0%
2025-11-06	$-0.74	$-0.66	+10.8%
2025-08-12	$-0.79	$-0.77	+2.5%
2025-05-14	$-0.76	$-1.15	-51.3%
2025-03-31	$0.45	$-18.32	-4171.1%

DCF fair valuemodel estimate

Intrinsic value

$3.82

Price

$27.66

Implied downside

-86%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
MAZEMaze Therapeutics, Inc.	$27.66	+0.49%	$1.5B	—
ARDXArdelyx, Inc.	$3.91	-1.51%	$966M	—
BCRXBioCryst Pharmaceuticals, Inc.	$9.81	-7.37%	$2.5B	—
IMNMImmunome, Inc.	$26.42	-5.61%	$2.5B	—
NTLAIntellia Therapeutics, Inc.	$11.83	-2.15%

Maze Therapeutics, Inc. Common Stock

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

www.mazetx.com

Employees: 141
IPO / List date: Jan 31, 2025
HQ: SOUTH SAN FRANCISCO, CA

Held by traders on TradeandTell

No one on the platform currently holds MAZE.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	15,800	$471.6K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded MAZE yet.

$MAZE chatter on StockTwits

Alpha Research@AlphaResearchHQ6d
JUST UPDATED ITS STOCK PORTFOLIO 📊 (Part 3) More positions from Google’s Q2 portfolio update: 🤖 $PATH — 7,034,337 shares 🧬 $PRME — 16,562,498 shares 🧪 $MAZE — 1,388,583 shares 💊 $RLAY — 1,410,029 shares 🚀 $BBOT — 2,823,126 shares This part of the portfolio shows continued exposure to emerging technology, automation, and biotech innovation. Institutional portfolios are always worth studying because they can reveal where long-term investors are willing to allocate capital. These names may not all move immediately, but understanding the themes behind the investments can provide valuable insight. I’ll continue tracking these companies and watching how the market reacts as these sectors develop. Save this one and revisit it when the market gives us the next signal.
View on StockTwits ↗
Mr. Denny@EquityResearch66d
GOOGLE $GOOGL JUST UPDATED ITS STOCK PORTFOLIO. Here are the major holdings as of the end of Q2: $GTLB — GitLab 2,724,712 shares $PATH — UiPath 7,034,337 shares $PRME — Prime Medicine 16,562,498 shares $MAZE — Maze Therapeutics 1,388,583 shares Google’s portfolio shows exposure across several long-term innovation themes. Big technology companies often invest years ahead of mainstream adoption. Watching where companies like Google deploy capital can provide insight into the future technology landscape. Follow my profile for more AI, space, and next-generation technology trends. NFA. DYOR.
View on StockTwits ↗
stockydennis@stockydennisJul 27
$MAZE so good
View on StockTwits ↗
stockydennis@stockydennisJul 24
$MAZE otsuka sanofi Novartis Someone is buying $MAZE shortly .
View on StockTwits ↗
MikeCaymanTrades@MikeCaymanTradesJul 5
$MAZE Signal Update Today's recommendation from our system is to STAY LONG. The previous BUY signal was issued on 06/17/2026, 15 days ago, when the stock price was 24.41. Since then, MAZE has risen by +28.06%. Weekly chart very bullish.
View on StockTwits ↗
Bullfinder@OlenaBullishJun 26
$MAZE Poet Technologies (NASDAQ: POET) remains highly volatile and speculative. While the stock has seen massive percentage gains in 2026, it is currently in a steep downward correction, recently falling to roughly $9.68 per share amid broader semiconductor sell-offs, profit-taking, and investor concerns about commercial scaling
View on StockTwits ↗
S Olsen@svertical1BullishJun 9
$MAZE $VRTX https://grok.com/share/c2hhcmQtMw_5c39ece5-ad7b-4374-a2fa-b3ca117c10b3 Both look great!
View on StockTwits ↗
M@justiceforb_85Jun 9
$MAZE anyone with insight on why MZR829 versus inaxaplin by $VRTX?
View on StockTwits ↗
SuperGreenToday@SuperGreenTodayMay 26
$MAZE Share Price: $25.95 Contract Selected: Jan 15, 2027 $35 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.80 – $0.97 Potential Upside: 77% ROI Time to Expiration: 233 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
Anthony-trading-with-Jesus@AnthonyTradingWithJesusBullishApr 27
$AI $MAZE $JOB $OMEX $CRM Good interview, very bullish, very transparent
View on StockTwits ↗
Al Gooding@almlkApr 8
$SPY $QQQ Start seeing RED in my watch list: $PLTR is the first RED followed by $APP, $MAZE Others start retreating from highs, decrease their gains.
View on StockTwits ↗
Streetwise Reports@StreetwiseReportsApr 7
San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial https://ow.ly/YB7J50YF5RP H.C. Wainwright reiterated its rating and price target on Maze Therapeutics ( $MAZE ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.
View on StockTwits ↗
Quantumup@QuantumupApr 2
Guggenheim⬇️ $UNCY's PT to $40, reiterated at Buy and said, We had a chance to catch up with the Unicycive management team yesterday after the company released their 4Q 2025 results earlier in the week. $MAZE TVTX SNY TAK $ARDX Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2039676564908945610?s=20
View on StockTwits ↗
Alain Bergeron@BestNwestBullishApr 1
$MAZE price target around 60$
View on StockTwits ↗
Don Wierwille@ItsAGreatDayApr 1
$MAZE Two great DOW and NASDAQ up days - MAZE seems dead! What the Crap!
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.